6MX.F - Eidos Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Currency in EUR

Valuation Measures

Market Cap (intraday) 52.04B
Enterprise Value 31.8B
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)76.34
Price/Book (mrq)12.25
Enterprise Value/Revenue 367.32
Enterprise Value/EBITDA 6-59.96

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3350.00%
S&P500 52-Week Change 318.19%
52 Week High 354.24
52 Week Low 39.95
50-Day Moving Average 343.89
200-Day Moving Average 335.42

Share Statistics

Avg Vol (3 month) 333
Avg Vol (10 day) 343
Shares Outstanding 537.5M
Float 9.84M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec. 31, 2018
Most Recent Quarter (mrq)Sep. 30, 2019

Profitability

Profit Margin -107.56%
Operating Margin (ttm)-112.52%

Management Effectiveness

Return on Assets (ttm)-10.75%
Return on Equity (ttm)-17.52%

Income Statement

Revenue (ttm)26.69M
Revenue Per Share (ttm)0.73
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -29.96M
Net Income Avi to Common (ttm)-28.71M
Diluted EPS (ttm)-0.79
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)165.82M
Total Cash Per Share (mrq)4.42
Total Debt (mrq)5.21M
Total Debt/Equity (mrq)3.18
Current Ratio (mrq)17.00
Book Value Per Share (mrq)4.37

Cash Flow Statement

Operating Cash Flow (ttm)-24.58M
Levered Free Cash Flow (ttm)-12.95M